Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large-cell lymphoma treated with brentuximab vedotin: A case series

被引：1
|
作者：
Contarini, Giorgia [1 ,2 ]
Carraro, Elisa [1 ]
Lovisa, Federica [2 ]
Martire, Gaia [1 ,2 ]
Lo Nigro, Luca [3 ]
Sala, Alessandra [4 ]
Pillon, Marta [1 ]
Mussolin, Lara [1 ,2 ]
机构：
[1] Univ Padua, Oncol & Stem Cell Transplant Ctr, Maternal & Child Hlth Dept Pediat Hematol, Padua, Italy
[2] Pediat Res Inst Citta Speranza, Padua, Italy
[3] Azienda Policlin San Marco, Ctr Pediat Hematol Oncol, Catania, Italy
[4] Univ Milano Bicocca, Fdn IRCCS San Gerardo Tintori, Ctr Maria Letizia Verga, Dept Pediat Hematol Oncol, Monza, Italy
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 204卷 / 01期
关键词：
CHILDREN;
D O I：
10.1111/bjh.19151
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：352 / 355
页数：4
相关论文
共 50 条
  • [1] Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma
    Lai, Chao-Ming
    Horowitz, Sandra
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (04) : 361 - 373
  • [2] BRENTUXIMAB VEDOTIN DESENSITIZATION IN A FEMALE WITH RELAPSED, REFRACTORY, ANAPLASTIC LARGE-CELL LYMPHOMA (ALCL)
    Qamar, N.
    Cho, S.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2012, 109 (05) : A68 - A68
  • [3] Relapsed or refractory anaplastic large cell lymphoma: Brentuximab vedotin of course!
    Paillassa, Jerome
    HEMATOLOGIE, 2018, 24 (01): : 19 - 21
  • [4] Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
    Ishizawa, Kenichi
    Yanai, Tomoko
    ADVANCES IN THERAPY, 2019, 36 (10) : 2679 - 2696
  • [5] Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
    Kenichi Ishizawa
    Tomoko Yanai
    Advances in Therapy, 2019, 36 : 2679 - 2696
  • [6] Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China
    Liu, Jia
    Zheng, Lei
    Chuang, Ling-Hsiang
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 99 - 107
  • [7] Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study
    Fukuhara, Noriko
    Yamamoto, Go
    Tsujimura, Hideki
    Chou, Takaaki
    Shibayama, Hirohiko
    Yanai, Tomoko
    Shibuya, Kazunori
    Izutsu, Koji
    LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 176 - 180
  • [8] Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature
    Zinzani, P. L.
    Sasse, S.
    Radford, J.
    Shonukan, O.
    Bonthapally, V.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 95 (03) : 359 - 369
  • [9] Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study
    Locatelli, Franco
    Mauz-Koerholz, Christine
    Neville, Kathleen
    Llort, Anna
    Beishuizen, Auke
    Daw, Stephen
    Pillon, Marta
    Aladjidi, Nathalie
    Klingebiel, Thomas
    Landman-Parker, Judith
    Medina-Sanson, Aurora
    August, Keith
    Sachs, Jessica
    Hoffman, Kristen
    Kinley, Judith
    Song, Sam
    Song, Gregory
    Zhang, Stephen
    Suri, Ajit
    Gore, Lia
    LANCET HAEMATOLOGY, 2018, 5 (10): : E450 - E461
  • [10] Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin
    Chihara, Dai
    Wong, Shannon
    Feldman, Tatyana
    Fanale, Michelle A.
    Sanchez, Larysa
    Connors, Joseph M.
    Savage, Kerry J.
    Oki, Yasuhiro
    HEMATOLOGICAL ONCOLOGY, 2019, 37 (01) : 35 - 38
12345